## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.9% below STRENGTH zone (3.0-6.0%); PEG 2.30 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Veterinary Medicine Market Size to Hit USD 98.51 Billion by 2033, Growing at a CAGR of 8.11% - SNS Insider**
- Source: GlobeNewswire | 20251220T040000 | Somewhat-Bullish | Relevance: 83%
- The global veterinary medicine market is projected to reach USD 98.51 billion by 2033, growing at an 8.11% CAGR from 2026, driven by factors like increasing pet adoption, rising prevalence of zoonotic diseases, and growing demand for preventive animal healthcare. Key drivers also include technological advancements in diagnostics, government initiatives, and the rise of online veterinary pharmacies. North America currently dominates the market, while Asia Pacific is expected to exhibit the fastest growth.

**2. Wall Street Zen Downgrades Elanco Animal Health (NYSE:ELAN) to Buy**
- Source: MarketBeat | 20251220T065239 | Bullish | Relevance: 60%
- Wall Street Zen downgraded Elanco Animal Health (NYSE:ELAN) from "strong-buy" to "buy," though the analyst consensus remains a "Moderate Buy." The company recently reported Q3 results that beat expectations, prompting adjusted FY2025 guidance. Insider activity shows recent purchases by the CEO and another insider, totaling significant share acquisitions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 16.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.30 elevated, pricing in significant growth expectations. Forward P/E 18.3x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.9B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.30 |
| Forward P/E | 18.3 |
| Current P/E | 19.5 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.6% to 1.9% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.1pp (needs >3.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.83x), long-term trend not supportive. MACD histogram positive (0.98), confirming momentum. RSI neutral at 51. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.92% (CS: 80) | Neutral |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | 0.98 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.833x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.77
- **Stop Loss:** $117.39 (5.2% risk)
- **Target:** $130.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 188
- **Position Value:** $23,268.76
- **Portfolio %:** 23.27%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*